jittawit.21/iStock via Getty Images
- Danaher (NYSE:DHR) has inked an agreement with AstraZeneca (NASDAQ:AZN) to develop diagnostic tests and tools that will help doctors determine which precision medicine treatments are best for individual patients.
- The first product envisioned for development will use technologies from Leica Biosystems, a Danaher’s subsidiary. And the initial focus “will be on digital and computational pathology products and AI-assisted algorithms, to help clinicians better diagnose patients by identifying those who are most likely to benefit from targeted therapies.”
- The partnership will also utilize the new Danaher Centers for Enabling Precision Medicine.
More on Danaher, AstraZeneca
- Why AstraZeneca May Be 2025’s Most Underrated Pharma Stock
- Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)
- Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity
- SA Asks: What are the best oncology stocks right now?
- AstraZeneca wins EU backing for Imfinzi in bladder cancer